|
1
|
Lee T, Teng TZJ and Shelat VG:
Carbohydrate antigen 19-9 - tumor marker: Past, present, and
future. World J Gastrointest Surg. 12:468–490. 2020.PubMed/NCBI View Article : Google Scholar
|
|
2
|
Rokhgireh S, Mehdizadeh Kashi A, Chaichian
S, Delbandi AA, Allahqoli L, Ahmadi-Pishkuhi M, Khodaverdi S and
Alkatout I: The diagnostic accuracy of combined Enolase/Cr, CA125,
and CA19-9 in the detection of endometriosis. Biomed Res Int.
2020(5208279)2020.PubMed/NCBI View Article : Google Scholar
|
|
3
|
Kim S, Park BK, Seo JH, Choi J, Choi JW,
Lee CK, Chung JB, Park Y and Kim DW: Carbohydrate antigen 19-9
elevation without evidence of malignant or pancreatobiliary
diseases. Sci Rep. 10(8820)2020.PubMed/NCBI View Article : Google Scholar
|
|
4
|
Omole F, Simmons BJ and Hacker Y:
Management of Bartholin's duct cyst and gland abscess. Am Fam
Physician. 68:135–140. 2003.PubMed/NCBI
|
|
5
|
Zheng L, Shan L and Cai F: Uterine
adenomyotic cyst with markedly elevated serum CA19-9 and CA125
levels: A case report. Exp Ther Med. 24(665)2022.PubMed/NCBI View Article : Google Scholar
|
|
6
|
Imaoka I, Kaji Y, Kobashi Y, Wada A, Honjo
G, Hayashi M, Yoshida M and Matsuo M: Cystic adenomyosis with
florid glandular differentiation mimicking ovarian malignancy. Br J
Radiol. 78:558–561. 2005.PubMed/NCBI View Article : Google Scholar
|
|
7
|
Takemori M and Sugimura K: Ovarian
chocolate cyst with markedly elevated serum CA19-9 level: A case
report. Eur J Obstet Gynecol Reprod Biol. 42:241–244.
1991.PubMed/NCBI View Article : Google Scholar
|
|
8
|
Sato H, Borsari R, Yajima EK, Ninomiya T,
Saito CS and Kumagai CA: Adenomyoma associated with high level of
CA 125 and CA 19-9: Case report. Eur J Gynaecol Oncol. 32:455–456.
2011.PubMed/NCBI
|
|
9
|
Wang L, Wang D, Zheng G, Yang Y, Du L,
Dong Z, Zhang X and Wang C: Clinical evaluation and therapeutic
monitoring value of serum tumor markers in lung cancer. Int J Biol
Markers. 31:e80–e87. 2016.PubMed/NCBI View Article : Google Scholar
|
|
10
|
Xiang DK, Xie JY, Luo W, Zou H and Wang D:
Systematic Analysis of Carbohydrate Antigen (CA19-9) within Serum
Multiple Tumor Markers Chip and its Clinical Significance in Cancer
Diagnosis. Practical Journal of Cancer. 27:147–152. 2012.(In
Chinese).
|
|
11
|
Luo XZ, Yang X and Fu WL: Evaluation of
the diagnostic value of CA19-9 combined with routine blood and
liver function indicators for pancreatic cancer. Inter J Laborat
Med. 43:1434–1439. 2022.(In Chinese).
|
|
12
|
Zhang K, Zhang LF, Zheng LX, et al:
Clinical predictive value of different serological indexes for
acute cholangitis secondary to choledocholithiasis. J Region
Anatomy Operat Surg. 31:512–515. 2022.(In Chinese).
|
|
13
|
Li X, Yan J, Meng WB, Zhang L, Zhou W, Zhu
K, Zhu X, He W and Bai Z: Department of General Surgery, the First
Hospital of Lanzhou University. Clinical value of serum
carbohydrate antigen 19-9 in the differential diagnosis of benign
and malignant biliary system diseases. Chin J Hepatic Surg
(Electronic Edition). 3:226–230. 2014.(In Chinese).
|
|
14
|
Sun W, Wang Q, Liu J, et al: Application
of serum tumor markers in the diagnosis of colorectal cancer. Chin
J Laborat Med. 23:10–12. 2000.(In Chinese).
|
|
15
|
Zhang XD, Ge XL, Liu SC, Zheng WQ and Shen
T: The prognostic and predictive value of serum CA199 and CEA in
colorectal cancer metastasis. Chin J Disease Control Prevent.
22:57–61. 2018.(In Chinese).
|
|
16
|
Wu AJ and Zhang ZX: Value of preoperative
multi-slice spiral CT enhancement scanning in determining TNM stage
of gastric cancer and its relationship with tumor markers and
proliferation molecule expression. J Hainan Med Univ. 22:2928–2931.
2016.(In Chinese).
|
|
17
|
Wang H and Yin Y: The expression
difference of CEA, CA19-9, CA72-4 and CA125 in patients with
different staging of gastric cancer and the relationship with
metastasis and recurrence. Biomed Res. 28:9769–9772. 2017.
|
|
18
|
Yue LJ, Hou XL, Xue L, Zhu H-C, Zhang J-J
and Wang Y: Department of Oncology, Hanzhong Central Hospital.
Clinical value of combined detection of multiple tumor markers in
diagnosis of the recurrence of ovarian cancer. Chin J Clin Oncol
Rehab. 27:20–22. 2020.(In Chinese).
|
|
19
|
Han XD, Ying S and Chen ZY: Analysis of
serum CA19-9 test results in healthy physical examination
population. Shanghai J Prevent Med. 25:109–110. 2013.(In
Chinese).
|
|
20
|
Zurli L, Decker J, Robles B and Regimbeau
JM: Atypic large hepatic cyst with persistent elevated CA19.9 serum
value: utility of intracystic CA72.4 dosage for a mini-invasive
management. Clin J Gastroenterol. 14:258–262. 2021.PubMed/NCBI View Article : Google Scholar
|
|
21
|
Yan XQ, Huang QL and He YH: Correlation
research of serum CA1 9-9 with benign cystic diseases. Guizhou Med
J. 47:176–177. 2023.(In Chinese).
|
|
22
|
Liu YH, Liu YQ and Qiu YH: Expression and
clinical value of vascular endothelial growth factor, carbohydrate
antigen 125, and carbohydrate antigen 19-9 in cervical cancer.
Oncology Progress. 20:712–715. 2022.
|
|
23
|
Chen YE, Wu XM and Wen YH: Expression of
serum HE4, CA125 and CA19-9 in patients with endometrial carcinoma
and its relationship with clinicopathological features. Chin J
Gerontol. 37:3787–3789. 2017.(In Chinese).
|
|
24
|
Fan CM, Luo X and Wen F: Clinical Value of
Serum CA125 and CA19-9 Detection for the Diagnosis of Epithelial
Ovarian Cancer and Endometriosis. J Chin Med Univ. 38:376–378.
2009.(In Chinese).
|
|
25
|
Zhang Q and Jin X: Relationship of
dyscrasia formation and the concentration of tumor necrosis
factor-α (TNF-α) and interleukin-6 (IL-6) of patients with advanced
gastrointestinal cancer. Chin Modern Doctor. 52:129–131. 2014.(In
Chinese).
|
|
26
|
Agca S and Kir S: The role of
interleukin-6 family cytokines in cancer cachexia. FEBS J.
291:4009–4023. 2024.PubMed/NCBI View Article : Google Scholar
|
|
27
|
Hannan CJ, Lewis D, O'Leary C, Donofrio
CA, Evans DG, Stapleton E, Freeman SR, Lloyd SK, Rutherford SA,
Hammerbeck-Ward C, et al: Beyond antoni: A surgeon's guide to the
vestibular schwannoma microenvironment. J Neurol Surg B Skull Base.
83:1–10. 2020.PubMed/NCBI View Article : Google Scholar
|
|
28
|
Cho HY, Kim K, Jeon YT, Kim YB and No JH:
CA19-9 elevation in ovarian mature cystic teratoma: Discrimination
from ovarian cancer - CA19-9 level in teratoma. Med Sci Monit.
19:230–235. 2013.PubMed/NCBI View Article : Google Scholar
|
|
29
|
Pontrelli G, Bounous VE, Scarperi S,
Minelli L, Di Spiezio Sardo A and Florio P: Rare case of giant
cystic adenomyoma mimicking a uterine malformation, diagnosed and
treated by hysteroscopy. J Obstet Gynaecol Res. 41:1300–1304.
2015.PubMed/NCBI View Article : Google Scholar
|
|
30
|
Trapé J, Fernández-Galán E, Auge JM,
Carbonell-Prat M, Filella X, Miró-Cañís S and González-Fernández C:
Oncology biomarkers section of the catalan association of clinical
laboratory science. Factors influencing blood tumor marker
concentrations in the absence of neoplasia. Tumour Biol.
46(s1):S35–S63. 2024.PubMed/NCBI View Article : Google Scholar
|
|
31
|
Yu L: Common tumor markers and their
clinical detection applications. Medical Information. 24:3494–3495.
2011.
|
|
32
|
Han M, Ma MJ and Lian J: Clinical value of
combined detection of serum AFP,CEA,CA199,CA125 and HE4 in
diagnosis of ovarian cancer. Hebei Med J. 44:76–78, 82. 2022.(In
Chinese).
|
|
33
|
Wu HJ, He NA, Xie L, et al: Application of
contrast-enhanced ultrasound combined with serum CA19-9 in the
differential diagnosis of cholangiocarcinoma and hepatocellular
carcinoma. J Practical Hepatol. 24:903–906. 2021.(In Chinese).
|
